| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2947 |
| Trial ID | NCT05260957 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | mosunetuzumab/polatuzumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). |
| Year | 2022 |
| Country | United States |
| Company sponsor | Lazaros Lekakis |
| Other ID(s) | 20210828 |
| Cohort 1 | |||||||||
|
|||||||||